Press Releases

Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus' EGFR/MET bispecific antibody (also known as PM1080) in Greater China, including Mainland China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by Biotheus the exclusive rights to develop, c

Telix Pharmaceuticals Limited, Telix, today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. The acquisition of Optimal Tracers will bolster Telix's in-house radiochemistry development capability, by adding a highly skilled team to Telix and esta

aTyr Pharma, Inc. a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The publication, entitled, “Efzofitimod for the

Rigel Pharmaceuticals, Inc. today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1 results of the Phase 1/2 study of olutasidenib, an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1). Olutasidenib was assessed as a monotherapy or in combination with azacitidine, in patients with mIDH1 acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The published data suggest that olutasidenib, with or without

Karo Pharma Aktiebolag's application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma's share on Nasdaq First North Growth Market will be 24 November 2022. As previously announced, Karo Pharma has applied for de-listing of the Company's shares from Nasdaq First North Growth Market. Nasdaq has now approved the application and resolved that the last day of trading will be 24 November 2022. For further information, ple

Kintor Pharmaceutical Limited a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been selected for oral presentation at the annual meeting of the American Society of Hematology 2022 (ASH 2022), and the abstract is available on ASH's official website. The ASH annual meeting is the largest conference worldwide of hematology, bringing together basi

Ascentage Pharma a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearanc

Insilico Medicine, a clinical stage artificial intelligence driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. “We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery,” said Changchun

SAB Biotherapeutics a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the company will be attending and presenting at this year’s U.S. Pharma Partnering Summit, being held on Nov. 17-18 in Boston, MA. The Pharma Partnering Summit brings together dealmakers of leading life science companies to disseminate knowledge through ex

BioMarin Pharmaceutical Inc., announced today a progress update on its Biologics License Application (BLA) for valoctocogene roxaparvovec AAV gene therapy for adults with severe Hemophilia A that is currently under review by the U.S. Food and Drug Administration (FDA).  As part of their review of the BLA, the FDA has scheduled its Pre-Licensure Inspection (PLI) of BioMarin's gene therapy manufacturing facility, located in Novato, CA. As anticipated, the FDA also has requested that th